1583 related articles for article (PubMed ID: 33563543)
1. Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity.
Opdenakker G; Van Damme J
Cytokine Growth Factor Rev; 2021 Apr; 58():134-140. PubMed ID: 33563543
[TBL] [Abstract][Full Text] [Related]
2. Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors.
Quarleri J; Delpino MV
Cytokine Growth Factor Rev; 2021 Apr; 58():55-65. PubMed ID: 33608189
[TBL] [Abstract][Full Text] [Related]
3. The intersection of COVID-19 and autoimmunity.
Knight JS; Caricchio R; Casanova JL; Combes AJ; Diamond B; Fox SE; Hanauer DA; James JA; Kanthi Y; Ladd V; Mehta P; Ring AM; Sanz I; Selmi C; Tracy RP; Utz PJ; Wagner CA; Wang JY; McCune WJ
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34710063
[TBL] [Abstract][Full Text] [Related]
4. Human genetics of SARS-CoV-2 infection and critical COVID-19.
Mogensen TH
Clin Microbiol Infect; 2022 Nov; 28(11):1417-1421. PubMed ID: 35218979
[TBL] [Abstract][Full Text] [Related]
5. Type I Interferon and the Spectrum of Susceptibility to Viral Infection and Autoimmune Disease: A Shared Genomic Signature.
Sugrue JA; Bourke NM; O'Farrelly C
Front Immunol; 2021; 12():757249. PubMed ID: 34917078
[TBL] [Abstract][Full Text] [Related]
6. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α.
Mathian A; Breillat P; Dorgham K; Bastard P; Charre C; Lhote R; Quentric P; Moyon Q; Mariaggi AA; Mouries-Martin S; Mellot C; Anna F; Haroche J; Cohen-Aubart F; Sterlin D; Zahr N; Gervais A; Le Voyer T; Bizien L; Amiot Q; Pha M; Hié M; Chasset F; Yssel H; Miyara M; Charneau P; Ghillani-Dalbin P; Casanova JL; Rozenberg F; Amoura Z; Gorochov G
Ann Rheum Dis; 2022 Dec; 81(12):1695-1703. PubMed ID: 35973806
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies to Interferons in Infectious Diseases.
Quiros-Roldan E; Sottini A; Signorini SG; Serana F; Tiecco G; Imberti L
Viruses; 2023 May; 15(5):. PubMed ID: 37243300
[TBL] [Abstract][Full Text] [Related]
8. Remnant Epitopes Generating Autoimmunity: From Model to Useful Paradigm.
Opdenakker G; Abu El-Asrar A; Van Damme J
Trends Immunol; 2020 May; 41(5):367-378. PubMed ID: 32299652
[TBL] [Abstract][Full Text] [Related]
9. Genetic associations in type I interferon related pathways with autoimmunity.
Delgado-Vega AM; Alarcón-Riquelme ME; Kozyrev SV
Arthritis Res Ther; 2010; 12 Suppl 1(Suppl 1):S2. PubMed ID: 20392289
[TBL] [Abstract][Full Text] [Related]
10. Host Genetics at the Intersection of Autoimmunity and COVID-19: A Potential Key for Heterogeneous COVID-19 Severity.
Karaderi T; Bareke H; Kunter I; Seytanoglu A; Cagnan I; Balci D; Barin B; Hocaoglu MB; Rahmioglu N; Asilmaz E; Taneri B
Front Immunol; 2020; 11():586111. PubMed ID: 33414783
[TBL] [Abstract][Full Text] [Related]
11. Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?
Kabeerdoss J; Danda D
Int J Rheum Dis; 2020 Aug; 23(8):998-1008. PubMed ID: 32779341
[TBL] [Abstract][Full Text] [Related]
12. Monogenic autoimmunity and infectious diseases: the double-edged sword of immune dysregulation.
Bigley TM; Cooper MA
Curr Opin Immunol; 2021 Oct; 72():230-238. PubMed ID: 34265589
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia.
Vanker M; Särekannu K; Fekkar A; Jørgensen SE; Haljasmägi L; Kallaste A; Kisand K; Lember M; Peterson P; Menon M; Hussell T; Knight S; Moore-Stanley J; Bastard P; Zhang SY; Mogensen TH; Philippot Q; Zhang Q; Puel A; Casanova JL; Kisand K
J Interferon Cytokine Res; 2023 Sep; 43(9):379-393. PubMed ID: 37253131
[TBL] [Abstract][Full Text] [Related]
14. Does autoimmune vitiligo protect against COVID-19 disease?
Post NF; Luiten RM; Wolkerstorfer A; Bekkenk MW; Böhm M
Exp Dermatol; 2021 Sep; 30(9):1254-1257. PubMed ID: 34081788
[TBL] [Abstract][Full Text] [Related]
15. Immunopathogenic mechanisms of systemic autoimmune disease.
Wahren-Herlenius M; Dörner T
Lancet; 2013 Aug; 382(9894):819-31. PubMed ID: 23993191
[TBL] [Abstract][Full Text] [Related]
16. Interferon system deficiencies exacerbating severe pandemic virus infections.
Stertz S; Hale BG
Trends Microbiol; 2021 Nov; 29(11):973-982. PubMed ID: 33757684
[TBL] [Abstract][Full Text] [Related]
17. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.
Meager A; Visvalingam K; Peterson P; Möll K; Murumägi A; Krohn K; Eskelin P; Perheentupa J; Husebye E; Kadota Y; Willcox N
PLoS Med; 2006 Jul; 3(7):e289. PubMed ID: 16784312
[TBL] [Abstract][Full Text] [Related]
18. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
Solimani F; Meier K; Ghoreschi K
Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 triggering autoimmune diseases.
Mobasheri L; Nasirpour MH; Masoumi E; Azarnaminy AF; Jafari M; Esmaeili SA
Cytokine; 2022 Jun; 154():155873. PubMed ID: 35461172
[TBL] [Abstract][Full Text] [Related]
20. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
